Document is current
Any future updates will be listed below
-
Authors
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
Aryankalayil, Molykutty J.
Coleman, C. Norman
Formenti, Silvia C. https://orcid.org/0000-0002-8227-8924
- License Information
-
More Information
Article History
Accepted: 9 May 2023
First Online: 6 June 2023
Competing interests
: L.G. has received research funding from Lytix Biopharma, Onxeo and Promontory; has received honoraria for consulting or advisory roles from AstraZeneca, Boehringer Ingelheim, EduCom, Imvax, Inzen, the Luke Heller TECPR2 Foundation, Noxopharm, OmniSEQ, Onxeo, Promontory, Sotio and The Longevity Labs; and holds stock options in Promontory. S.C.F. has received research funding from Bristol Myers Squibb, Celldex, Eisai, Eli-Lilly, Merck, Regeneron and Varian; and has received honoraria for consulting or advisory roles from Accuray, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Elekta, EMD Serono, Genentech, MedImmune, Merck, Nanobiotix, Regeneron, Roche, Varian and View Ray. The other authors declare no competing interests.
